Molecular mechanisms in the antiproliferative action of taxol and tiazofurin

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2469-2477

  Olah, Edith ^a   Csokay, Bela ^a   Prajda, Noemi ^a   Kote Jarai, Zsofia ^a   Yeh, Y Albert ^b   Weber, George ^b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Apoptosis; Differentiation; K562; MCF 7; OVCAR 5; Schedule dependency; Taxol; Tiazofurin

Indexed keywords

DNA FRAGMENT; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; PACLITAXEL; TIAZOFURIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOMA CELL; CELL DIFFERENTIATION; CELL STRAIN K 562; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE C MYC; ONCOGENE K RAS; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL DIVISION; CELL NUCLEUS; DNA FRAGMENTATION; DNA, NEOPLASM; DOWN-REGULATION; DRUG SYNERGISM; ERYTHROCYTES; FEMALE; GENES, MYC; GENES, RAS; HUMANS; IMP DEHYDROGENASE; LEUKEMIA; OVARIAN NEOPLASMS; PACLITAXEL; RIBAVIRIN; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0029909347     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rowinsky EK, McGuire WP and Donehower RC: The current status of taxol. Principles and Practice of Gynecologic Oncology Updates 1: 1-16, 1993.
2. Rowinsky EK, Cazenaeva LA, Burke PJ, Karp JE, Tucker RW, Ettinger DS and Donehower RC: Phase 1 and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49: 4640-4647, 1989.
3. Manfredi JJ and Horowitz SB: Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-125, 1984.
4. Tricot G, Jayaram HN, Weber G and Hoffman R: Tiazofurin: biological effects and clinical uses. Intl J Cell Cloning 8: 161-170. 1990.
5. Weber G: IMP dehydrogenase and GTP as targets in human leukemia treatment. Adv Exptl Med and Biol 309: 287-292, 1991.
6. Cooney DA, Jayaram HN, Gebeyeu G, Betts CR, Kelley JA, Marquez VE and Johns DG: The conversion of 2-ß-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibiting properties. Biochem Pharmacol 31: 2133-2136, 1982.
7. Jayaram HN, Dion RI, Glazer DG, Johns RK, Robins PC and Srivastava PC: Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-ß-D-ribofuranosylthiazole-4-carboxamide (NSC 296193). Biochem Pharmacol 31: 3839-3845, 1982.
8. Lui MS, Faderan MA, Liepnieks JJ, Natsumeda Y, Olah E, Jayaram HN and Weber G: Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-ß-D-ribofuranosylthiazole-4-carboxamide). J Biol Chem 259: 5078-5082, 1984.
9. Lucas DL, Robins RK, Knight RD and Wright DG: Induced maturation of the human promyelocytic leukemia cell line, HL-60, by 2-ß-D-ribofuranosylthiazole-4-carboxamide. Biochem Biophys Res Commun 115: 971-980, 1983.
10. Sokolski JA, Blair OC and Sartorelli AC: Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase. Cancer Res 46: 2314-2319, 1986.
11. Olah E, Natsumeda Y, Ikegami T, Kote Z, Horanyi M, Szelenyi J, Paulik E, Kremmer T, Hollan SR, Sugar J and Weber G: Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K562 leukemia cells. Proc Natl Acad Sci USA 85: 6533-6537, 1988.
12. Weber G, Nagai M, Natsumeda Y, Eble JN, Jayaram HN, Paulik E, Zhen W, Hoffman R and Tricot G: Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient. Cancer Commun 3: 61-66, 1991.
13. Dive C and Hickman JA: Drug-target interaction, only the first step in the commitment to a programmed cell death. Br J Cancer 64: 192-196, 1991.
14. Olah E, Lui MS, Tzeng DY and Weber G: Phase and cell cycle specificity of pyrazofurin action. Cancer Res 40: 2869-2875, 1980.
15. Kyprianou N and Isaacs JT: "Thymineless" death in androgen-independent prostatic cancer cells. Biochem Biophys Res Comm 165: 73-81, 1989.
16. Ikegami T, Natsumeda Y and Weber G: Direct assay method for inosine 5'-monophosphate dehydrogenase activity. Anal Biochem 150: 155-160, 1985.
17. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 62: 156-159, 1987.
18. Webb JL: "Enzyme and Metabolic Inhibitors" Vol. 1. Acad. Press, NY., pp.507-510, 1963.
19. Chou TC and Talalay P: Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
20. Olah E, Ezer R, Giaretti W and Eble J: Metabolic control of oncogene expression. Biochem Soc Transact 18: 72-74, 1989.
21. Jackson RC, Morris HP and Weber G: IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256: 331-333, 1975.
22. Weber G, Prajda N and Jackson RC: Key enzymes of IMP metabolism: Transformation-and proliferation-linked alterations in gene expression. Advan Enzyme Regul 14: 3-24, 1976.
23. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy. G.H.A. Clowes Memorial Lecture. Cancer Res 43: 3466-3492, 1983.
24. Maurer HR, Eckert K and Bissery MC: Taxotere inhibits the proliferation and induces the differentiation of HL-60 and K562 human myeloid leukemia cells in vitro. Intl J Oncol 3: 161-165, 1993.
25. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME and Huang Y: Taxol induces internucleosomal fragmentation associated with programmed death in human myeloid leukemia cells. Leukemia 7: 563-568, 1993.
26. Kerr JFR, Wyllie AH and Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implication in tissue kinetics. Br J Cancer 26: 239-257, 1972.
27. Muller R, Mumberg D and Lucibello FC: Signals and genes in the control of cell-cycle progression. Biochem Biophys Acta 1155: 151-179, 1993.
28. Ellis RE and Horvitz HR: Mechanisms and functions of cell death. Ann Rev Cell Biol 7: 663-698, 1991.
29. Olah E, Kote Zs, Natsumeda Y, Yamaji Y, Jarai G, Lapis E, Financsek I and Weber G: Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells. Cancer Biochem Biophys 1: 107-117, 1990.
30. Csokay B, Papp J, Besznyak I, Bosze P, Sarosi Z, Toth J, Zalay Z and Olah E: Oncogene patterns in breast and ovarian carcinomas. Eur J Surg Oncol 19: Suppl. 1, 593-599, 1993.
31. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128, 1992.
32. Taniki T, Prajda N, Monden Y and Weber G: Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells. Cancer Biochem Biophys 13: 295-302, 1993.
33. Look KY, Sutton GP, Natsumeda Y, Eble JN, Stehman FB, Ehrlich CE, Olah E, Prajda N, Bosze P, Eckhardt S and Weber G: Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase activity in extracts of ovarian carcinomas. Gyn Oncol 47: 66-70, 1992.
34. Saunders DA, Lawrence WD, Christensen C, Wappler NL, Malone JM, Malviya VK and Deppe G: Taxol-induced apoptosis in MCF-7 breast cancer cells. Proc Am Assoc Cancer Res 35: 317, 1994.
35. Yeh YA, Olah E, Wendel JJ, Sledge GW and Weber G: Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule dependence. Life Sci 54: 431-435, 1994.
36. Gangcmi RM, Tiso M, Marchetti C, Severi AB and Fabbi M: Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 36 (5): 385-392, 1995.
37. Liebermann D, Hoffmann B and Steinmann R: p53-dependent and independent pathways. Oncogene 11: 199-210, 1995.
38. Milross CG, Peters LJ, Hunter NR, Mason KA and Milas L: Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo. Intl J Cancer 62 (5): 599-504, 1995.